Mustang Bio, Inc. (MBIO) financial statements (2022 and earlier)

Company profile

Business Address 2 GANSEVOORT STREET
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments109,61897,80461,41334,07360,97727,499
Cash and cash equivalents109,61897,80461,41316,46934,97527,499
Short-term investments   17,60426,002 
Restricted cash and investments1,0001,0001,000   
Receivables   37106 
Prepaid expense   1,015278 
Other undisclosed current assets1,088730650   
Total current assets:111,70699,53463,06335,12561,36127,499
Noncurrent Assets
Operating lease, right-of-use asset1,0501,0881,196
Property, plant and equipment11,0528,0287,9366,858  
Restricted cash and investments1,0001,0001,000500500 
Other noncurrent assets362250250271251 
Other undisclosed noncurrent assets    1,381 
Total noncurrent assets:13,46410,36610,3827,6292,132 
TOTAL ASSETS:125,170109,90073,44542,75463,49327,499
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:9,7448,7475,6685,3813,474683
Accounts payable3,5123,5181,877   
Other undisclosed accounts payable and accrued liabilities6,2325,2293,7915,3813,474683
Debt 2781,507   
Due to related parties723490596  320
Other undisclosed current liabilities348  2361372,220
Total current liabilities:10,8159,5157,7715,6173,6113,223
Noncurrent Liabilities
Long-term debt and lease obligation1,6851,95014,022   
Long-term debt, excluding current maturities  12,179   
Operating lease, liability1,6851,9501,843
Liabilities, other than long-term debt270  74150 
Accounts payable and accrued liabilities   74150 
Deferred revenue270  
Total noncurrent liabilities:1,9551,95014,02274150 
Total liabilities:12,77011,46521,7936,3583,6613,223
Stockholders' equity
Stockholders' equity attributable to parent, including:112,40098,43551,65236,39659,83224,276
Common stock 74332
Common stock, value, subscriptions4,3297,9394,9232,0859,5584,396
Additional paid in capital359,906275,963172,184113,37898,67936,998
Accumulated deficit(251,844)(185,474)(125,459)(79,070)(48,408)(17,120)
Other undisclosed stockholders' equity attributable to parent9     
Total stockholders' equity:112,40098,43551,65236,39659,83224,276
TOTAL LIABILITIES AND EQUITY:125,170109,90073,44542,75463,49327,499

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Operating expenses(66,723)(56,806)(45,885)(31,223)(31,785)(11,363)
Operating loss:(66,723)(56,806)(45,885)(31,223)(31,785)(11,363)
Nonoperating income (expense)353(3,209)(504)561497(1,291)
Other nonoperating income353     
Interest and debt expense (3,917)(1,767)(8)(8)(253)
Net loss:(66,370)(63,932)(48,156)(30,670)(31,296)(12,907)
Other undisclosed net income attributable to parent 3,9171,76788253
Net loss available to common stockholders, diluted:(66,370)(60,015)(46,389)(30,662)(31,288)(12,654)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(66,370)(63,932)(48,156)(30,670)(31,296)(12,907)
Comprehensive loss, net of tax, attributable to parent:(66,370)(63,932)(48,156)(30,670)(31,296)(12,907)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: